Table 1 Patient characteristics
N (%) | All | XELOXIRI | XELOXIRI + BEV | XELOXIRI + CET |
|---|---|---|---|---|
61 (100) | 39 (63.9) | 18a (29.5) | 4 (6.6) | |
Sex | ||||
   Male | 38 (62.3) | 27 (44.3) | 9 (14.8) | 2 (3.3) |
   Female | 23 (37.7) | 12 (19.7) | 9 (14.8) | 2 (3.3) |
Age | ||||
   Median (range) | 50 (26–70) | 60 (27–70) | 38 (36–66) | 29.5 (26–46) |
    ≤ 65 years | 52 (85.2) | 31 (50.8) | 17 (27.9) | 4 (6.6) |
    > 65 years | 9 (14.8) | 8 (13.1) | 1 (1.6) | 0 |
ECOG | ||||
   0 | 20 (32.8) | 15 (24.6) | 4 (6.6) | 1 (1.6) |
   1 | 41 (68.3) | 24 (39.3) | 14 (23.0) | 3 (4.9) |
Primary location | ||||
   Right colon | 19 (31.1) | 13 (21.3) | 6 (9.8) | 0 |
   Left colon | 42 (68.9) | 26 (42.6) | 12 (19.7) | 4 (6.6) |
   Colon | 17 (27.9) | 6 (9.8) | 9 (14.8) | 2 (3.3) |
   Rectum | 25 (41.0) | 20 (32.8) | 3 (4.9) | 2 (3.3) |
Surgery on primary tumour | ||||
Yes | 7 (11.5) | 4 (6.6) | 3 (4.9) | 0 |
No | 54 (88.5) | 35 (57.4) | 15 (24.6) | 4 (6.6) |
(Neo)adjuvant chemotherapy | ||||
   Yes | 6 (9.8) | 3 (4.9) | 3 (4.9) | 0 |
   No | 55 (90.2) | 36 (59.0) | 15 (24.6) | 4 (6.6) |
(Neo)adjuvant radiotherapy | ||||
   Yes | 1 (1.6) | 1 (1.6) | 0 | 0 |
   No | 60 (98.4) | 38 (62.3) | 18 (29.5) | 4 (6.6) |
Time to metastasis | ||||
   synchronous | 56 (91.8) | 35 (57.4) | 17 (27.9) | 4 (6.6) |
   Metachronous | 5 (8.2) | 4 (6.6) | 1 (1.6) | 0 |
Metastasis sites | ||||
   Liver | 41 (67.2) | 27 (44.3) | 11 (18.0) | 3 (4.9) |
   Liver-only | 15 (24.6) | 9 (14.8) | 5 (8.2) | 1 (1.6) |
   Lung | 18 (29.5) | 12 | 6 (9.8) | 0 |
   Lung-only | 5 (8.2) | 4 (6.6) | 1 (1.6) | 0 |
   Peritoneum | 14 (23.0) | 8 (13.1) | 5 (8.2) | 1 (1.6) |
   Peritoneum-only | 7 | 3(4.9) | 3(4.9) | 1(1.6) |
Numbers of metastatic organs | ||||
   1 | 32 (52.5) | 20 (32.8) | 10 (16.4) | 2 (3.3) |
   2 | 18 (29.5) | 13 (21.3) | 4 (6.6) | 1 (1.6) |
    > 2 | 11 (18.0) | 6 (9.8) | 4 (6.6) | 1 (1.6) |
RAS and BRAF status | ||||
   RAS mutant | 23 (37.7) | 17 (27.9) | 6 (9.8) | 0 |
   BRAF mutant | 12 (19.7) | 4 (6.6) | 8 (13.1) | 0 |
   RAS/BRAF wild-type | 19 (31.1) | 13 (21.3) | 2a (3.3) | 4 (6.6) |
   Missing data | 7 (11.5) | 5 (8.2) | 2 (3.3) | 0 |
Primary tumour site and RAS/BRAF status | ||||
   Right and RAS/BRAF wild-type | 2 (3.3) | 1 (1.6) | 1 (1.6) | 0 |
   Right and RAS mutant | 11 (18.0) | 8 (13.1) | 3 (4.9) | 0 |
   Right and BRAF mutant | 2 (3.3) | 2 (3.3) | 0 | 0 |
   Left and RAS/BRAF wild-type | 17 (27.9) | 12 (19.7) | 1 (1.6) | 4 (6.6) |
   Left and RAS mutant | 12 (19.7) | 9 (14.8) | 3 (4.9) | 0 |
   Left and BRAF mutant | 10 (16.4) | 2 (3.3) | 8 (13.1) | 0 |
   Missing data | 7 (11.5) | 5 (8.2) | 2 (3.3) | 0 |